The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
Top Cited Papers
Open Access
- 14 December 2004
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (1) , 131-139
- https://doi.org/10.1038/sj.bjc.6602258
Abstract
The proto-oncogene RAS, coding for a 21 kDa protein (p21), is mutated in 20% of lung cancer. However, the literature remains controversial on its prognostic significance for survival in lung cancer. We performed a systematic review of the literature with meta-analysis to assess its possible prognostic value on survival. Published studies on lung cancer assessing prognostic value of RAS mutation or p21 overexpression on survival were identified by an electronic search. After a methodological assessment, we estimated individual hazard ratios (HR) estimating RAS protein alteration or RAS mutation effect on survival and combined them using meta-analytic methods. In total, 53 studies were found eligible, with 10 concerning the same cohorts of patients. Among the 43 remaining studies, the revelation method was immunohistochemistry (IHC) in nine and polymerase chain reaction (PCR) in 34. Results in terms of survival were significantly pejorative, significantly favourable, not significant and not conclusive in 9, 1, 31, 2, respectively. In total, 29 studies were evaluable for meta-analysis but we aggregated only the 28 dealing with non-small-cell lung cancer (NSCLC) and not the only one dealing with small-cell-lung cancer (SCLC). The quality scores were not statistically significantly different between studies with or without significant results in terms of survival, allowing us to perform a quantitative aggregation. The combined HR was 1.35 (95% CI: 1.16–1.56), showing a worse survival for NSCLC with KRAS2 mutations or p21 overexpression and, particularly, in adenocarcinomas (ADC) (HR 1.59; 95% CI 1.26–2.02) and in studies using PCR (HR 1.40; 95% CI 1.18–1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86–1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR.Keywords
This publication has 72 references indexed in Scilit:
- Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patientsCancer Letters, 2003
- Trimodality treatment in Stage III nonsmall cell lung carcinomaCancer, 2002
- Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genesGenes & Development, 2001
- A novel molecular staging protocol for non-small cell lung cancerOncogene, 1999
- Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinomaInternational Journal of Cancer, 1998
- Clinicopathologic Analysis of k-ras, p53, and ERBB-2 Gene Alterations in Pulmonary AdenocarcinomaDiagnostic Molecular Pathology, 1997
- Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in Stage IIIA non-small cell lung cancerLung Cancer, 1995
- Studies on Clinicopathological Features of Lung Cancer Patients with K-ras/p53 Gene Alterations: Comparison between Younger and Older GroupsOncology, 1995
- C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.Journal of Clinical Investigation, 1994
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985